Skip to content
Disclosery

Sanofi

Follow

13F filer, CIK 1121404, Paris, France

Sanofi reported $310,414,825 across 8 holdings for the quarter ended 2025-12-31, in a 13F-HR filed 2026-02-11.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001193125-26-045633

Period
2025-12-31
Reported value
$310M
Holdings
8
Top 10 weight
100%
New
1
Sold out
2

Largest buys vs the previous quarter

SecurityShares changeApprox. value
MPLTnew+912,041$16M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
OMDAexited-524,903-$11.6M
LAVA THERAPEUTICS NVexited-1,919,455-$2.99M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q4 2025

Share positions as resolved from 13F-HR 0001193125-26-045633, largest first. % of portfolio is the value over $310,414,825, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
MGTXMEIRAGTX HLDGS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 12,197,737 shares; 2025Q1: 12,197,737 shares; 2025Q2: 12,197,737 shares; 2025Q3: 12,197,737 shares; 2025Q4: 12,197,737 shares 12,197,737$97M31.24%0Timeline
INBXINHIBRX BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 1,157,926 shares; 2025Q1: 1,157,926 shares; 2025Q2: 1,157,926 shares; 2025Q3: 1,157,926 shares; 2025Q4: 1,157,926 shares 1,157,926$91.5M29.47%0Timeline
NVAXNOVAVAX INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 6,880,481 shares; 2025Q1: 6,880,481 shares; 2025Q2: 6,880,481 shares; 2025Q3: 6,880,481 shares; 2025Q4: 6,880,481 shares 6,880,481$46.2M14.9%0Timeline
ANABANAPTYSBIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 821,917 shares; 2025Q1: 821,917 shares; 2025Q2: 821,917 shares; 2025Q3: 821,917 shares; 2025Q4: 821,917 shares 821,917$39.8M12.84%0Timeline
IMRXIMMUNEERING CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 2,708,559 shares; 2025Q4: 2,708,559 shares 2,708,559$17.8M5.74%0Timeline
MPLTMAPLIGHT THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 912,041 shares 912,041$16M5.16%newTimeline
ELDNELEDON PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 814,980 shares; 2025Q1: 814,980 shares; 2025Q2: 814,980 shares; 2025Q3: 814,980 shares; 2025Q4: 814,980 shares 814,980$1.23M0.4%0Timeline
QTTBQ32 BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 244,083 shares; 2025Q1: 244,083 shares; 2025Q2: 244,083 shares; 2025Q3: 244,083 shares; 2025Q4: 244,083 shares 244,083$810K0.26%0Timeline

Sold out in Q4 2025

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
OMDAOMADA HEALTH INC524,903$11.6Mshares
LAVA THERAPEUTICS NVLAVA THERAPEUTICS NV1,919,455$2.99Mshares

How Q4 2025 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001193125-26-045633 base2026-02-11acceptance time not in the bulk data set